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Photochemical internalization (PCI) has been employed as a tool for site-specific intracellular delivery of a variety of molecules. In this study,
for the first time, PCI has been employed to facilitate the endosomal escape of small interfering RNA (siRNA) molecules, which are the functional
mediators of RNA interference (RNAi). In order to interact with the machinery that will induce post-transcriptional gene silencing, siRNA
molecules need to enter the cytoplasm of the cells. This study shows that one of the important rate-limiting steps of siRNA silencing efficiency is
the ability of siRNA molecules and/or complexes to escape from the endosomes into the cytosol of the cells. The target of this study, the epidermal
growth factor receptor (EGFR), is known as an attractive target for cancer therapy. In this study, a 10-fold increased efficiency in knockdown of
the EGFR protein was obtained when anti-EGFR siRNA treatment was combined with PCI as compared to siRNA treatment alone. The fact that
this combined treatment resulted in a stronger silencing efficiency indicates that lower doses of siRNA can be used when PCI is employed to
augment siRNA delivery. Lowering doses of siRNA would prevent saturation of the RNAi machinery and reduce off-target effects. In addition,
local illumination of target tissue would only induce PCI in the desired cells, which can further increase the specificity of the treatment, supporting
PCI as an attractive strategy to improve siRNA silencing efficiency.
© 2007 Elsevier B.V. All rights reserved.Keywords: EGFR; Photochemical internalization; siRNA; Silencing efficiency; Cancer therapy1. Introduction
The epidermal growth factor receptor (EGFR) is a recog-
nized target for cancer therapy. This transmembrane glycopro-
tein is known to be overexpressed in many tumors (e.g.,
colorectal, head and neck, lung, and ovarian carcinomas), and
its signaling pathway is involved in cell differentiation,
proliferation, migration, development of angiogenesis, and
apoptosis inhibition [1]. Furthermore, expression of EGFR is
associated with poor treatment responses and fast disease
progression. Strategies have been developed to interfere with
EGFR signaling; in particular, monoclonal antibodies (mAbs)
and tyrosine kinase inhibitors (TKIs) have been broadly
explored [2]. Alternative strategies, such as RNA interference
(RNAi), aim at reducing the expression of EGFR protein [1].⁎ Corresponding author. Tel.: +31 30 253 9392; fax: +31 30 251 7839.
E-mail address: R.M.Schiffelers@pharm.uu.nl (R.M. Schiffelers).
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doi:10.1016/j.bbamem.2007.01.013Small interfering RNA (siRNA) molecules are the functional
mediators of RNAi, a mechanism able to interrupt the
translation of a specific protein by inducing post-transcriptional
gene silencing. The cleavage of mRNA, induced by siRNA
molecules with a complementary sequence, gives the opportu-
nity to design siRNAs that inhibit the expression of specific
proteins responsible for pathologies [3], such as EGFR.
Nevertheless, in order to functionally silence EGFR expression,
siRNA molecules need to be present in the cytoplasm of the
EGFR-expressing tumor cells to interact with the RNAi
machinery. The physicochemical properties of siRNA, featured
by relatively high molecular weight and strong negative charge,
impede cell membrane translocation. As a consequence, a
variety of (viral and non-viral) delivery systems have been
proposed [3]. Non-viral based carriers, like cationic lipoplexes
and polyplexes, are usually taken up by cells through charge-
based binding and endocytosis. Once inside the endosomes,
these complexes need to efficiently escape into the cytosol,
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Some of the carrier materials are known to be able to destabilize
the endosomal membrane by themselves, by acting as a proton
sponge or a fusogen [4]. Nevertheless, a number of additional
mechanisms have been proposed to facilitate the escape of
particles from the endosomes, such as photochemical inter-
nalization (PCI).
PCI was first presented in 1999 [5] as a novel technology for
the delivery of a variety of therapeutic molecules into the
cytosol. Since then, several studies have been published, demon-
strating that this technique can be used, both in vitro and in vivo
[6–8], for site-specific delivery of macromolecules, namely
proteins [5], peptides [5], peptide nucleic acids [9,10], and
plasmid DNA carried by non-viral [5,11,12] and viral-based
carrier systems [13]. PCI technology employs specific, pre-
ferably amphiphilic [14], photosensitizing compounds which
accumulate in the membranes of the endocytic vesicles. Upon
illumination, such photosensitizers (PS) become excited, and
subsequently induce the formation of reactive oxygen species,
primarily singlet oxygen. This highly reactive intermediate can
damage cellular components, but the short range of action and
short life-time, confine the damaging effect to the production
site. This localized effect induces the disruption of the endocytic
vesicles, thereby releasing the entrapped therapeutic molecules
into the cytosol [5].
The aim of this study was to determine whether siRNA-
mediated silencing of EGFR could be enhanced using PCI as a
tool to improve the endosomal escape of anti-EGFR siRNA
and, if so, to determine the extent of the silencing improvement.
2. Materials and methods
2.1. Cell line and culture conditions
The human epidermoid carcinoma cell line A431 was kindly given by Dr.
Paul M. P. van Bergen en Henegouwen (Institute of Biomembranes, Utrecht
University, The Netherlands). A431 cells were subcultured in Dulbecco's
modified Eagle's medium containing 3.7 g/l sodium bicarbonate, 4.5 g/l
L-glucose (Gibco BRL, Breda, The Netherlands) and supplemented with
L-glutamine (2 mM), 7.5% (v/v) foetal bovine serum, penicillin (100 IU/ml),
streptomycin (100 μg/ml), and amphotericin B (0.25 μg/ml), at 37 °C in a
humidified atmosphere containing 5% CO2.
2.2. Photosensitizer and light source
The photosensitizer (PS) TPPS2a, meso-tetraphenylporphine with two
sulfonate groups on adjacent phenyl rings, was kindly provided by Dr. Anders
Høgset (PCI Biotech AS, Oslo, Norway). The PS was light protected and stored
at −20 °C until use. Cells were exposed to blue light from the LumiSource®, a
bank of four light tubes emitting light in the region of 375–450 nm, with 13
mW/cm2 irradiance (PCI Biotech AS, Oslo, Norway).
2.3. Preparation of siRNA/LF complexes and treatment of cells
Complexes of anti-EGFR siRNA and Lipofectamine (anti-EGFR siRNA/
LF) were prepared by gently mixing 20, 40 and 80 pmol of anti-EGFR siRNA
(Eurogentec, Maastricht, The Netherlands) in 50 μl of 5 mM HEPES (pH 7.4),
with 1, 2 and 4 μl Lipofectamine (Invitrogen, Breda, The Netherlands) in 50 μl
of 5 mM HEPES (pH 7.4), respectively. The solutions were incubated 15 min at
room temperature and then added to the cells, resulting in a final concentration
of 40, 80 and 160 pmol/ml of anti-EGFR siRNA in the wells. One day afterseeding, the cells were incubated with 0.1–1.0 μg/ml PS, in complete culture
medium, for 18 h at 37 °C. After this, the medium was removed, cells were
washed and fresh medium was added to the wells. Thereafter, the anti-EGFR
siRNA/LF complexes were added to the cells and incubated for 5 h. Then, the
medium was removed, cells were washed and fresh medium was added to the
wells. Cells were then exposed to the light source for 60, 75, or 90 s, and then
incubated at 37 °C for 2 days, after which the EGFR protein expression was
analyzed, either by flow cytometry or Western blot.
Complexes of non-specific (NS) siRNAwere prepared with anti-Luc siRNA
(Qiagen, Venlo, The Netherlands) and Lipofectamine as described above.
2.4. Cell proliferation assay
Four thousand cells were seeded per well of 96-well plates and treated as
described above, except for the addition of anti-EGFR siRNA/LF complexes.
Immediately after illumination of the cells, BrdU reagent was added to the cells
and 24 h later the ELISA BrdU-colorimetric immunoassay (Roche Applied
Science, Penzberg, Germany) was performed as recommended by the
manufacturer. After adding 25 μl of 1 M H2SO4 to interrupt the colorimetric
reaction, the absorbance at 450 nm was measured, with the reference wavelength
set to 655 nm, using a Bio-Rad Novapath Microplate Reader (Bio-Rad
Laboratories, Veenendaal, The Netherlands).
2.5. Confocal microscopy
For confocal laser-scanning microscopy analysis, 6×104 cells were seeded
per well of 12-well plates, on gelatine coated (Sigma-Aldrich, Zwijndrecht, The
Netherlands) coverslips. The cells were incubated with 0.5 μg/ml of PS and
washed as described above. For this experiment the complexes were prepared
with Alexa633-labelled siRNA (Eurogentec, Maastricht, The Netherlands) and
Lipofectamine, in the same way as described earlier, with a final concentration
of 100 pmol/ml of Alexa633-labelled siRNA per well. EGF-Alexa488
(Molecular Probes, Breda, The Netherlands) was added to the wells
(0.25 μg/ml) together with the complexes. The cells were fixed with a 4%
formaldehyde (Fluka, Zwijndrecht, The Netherlands) solution in PBS, for
30 min at room temperature, after 4-h incubation or few minutes after the 75 s
illumination step. After fixation, cells were washed twice with PBS and
mounted on glass cover slides, using FluorSave (Calbiochem, San Diego, CA,
USA). The cells were then analyzed on a Leica TCS-SP confocal laser-
scanning microscope (Leica, Heidelberg, Germany) equipped with three lasers:
488-nm argon, 568-nm krypton, and 647-nm HeNe laser.
2.6. Flow cytometry analysis
Forty thousand cells were seeded per well of 24-well plates and treated as
described earlier. Two days later, the cells were trypsinized, washed with PBA
buffer (phosphate-buffered saline supplemented with 0.3% BSA and 0.03%
sodium azide) and resuspended in 100 μl PBA buffer. The cells were then
incubated with either a specific anti-EGFR monoclonal antibody, or a non-
specific antibody, both labelled with FITC (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), for 30 min. Thereafter, the cells were washed twice with
PBA, resuspended in 300 μl PBA and analyzed using a FACScalibur (Becton
and Dickinson, Mountain View, CA, USA). Dead cells were discriminated from
viable cells by adding propidium iodide (Molecular Probes, Breda, The
Netherlands) to a final concentration of 1 μg/ml. The data were analyzed with
Summit® software (DakoCytomation, Fort Collins, CO, USA) and for relative
quantification, the mean fluorescence intensity times the percentage of positive
events was used. Generally 10,000 cells were analyzed during each mea-
surement, and samples were prepared in triplicates.
2.7. Western blot
Eighty thousand cells were seeded per well of 6-well plates and 48 h after the
previously described treatment with anti-EGFR siRNA/LF complexes, cells
were lysed with RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, containing
1 mM PMSF and 150 μl/ml of complete EDTA-free mini tablet protease
Fig. 1. Release of siRNA in the cytoplasm after PCI. Confocal microscopy
images show cells incubated for 4 h with siRNA-Alexa633/LF complexes (red)
and EGF-Alexa488 (green) (a), and cells which were illuminated after the 4-h
incubation (b). The punctuated pattern (a), most likely indicating localization in
endocytic vesicles, as suggested by co-localization (yellow, in the overlay
image) of complexes and EGF-Alexa488, gives place to a less punctuated and
more diffuse pattern (b) where the fluorescence is spread throughout the
cytoplasm of the cells. Cells were previously incubated with PS, as described in
Materials and methods.
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20 min on ice. The lysates were collected and concentrated using centrifugal
filters with a molecular weight cut-off of 10 kDa (Microcon, Millipore,
Amsterdam, The Netherlands). The total protein content was measured using the
Micro BCA assay (Pierce, Rockford, USA), and samples were prepared with
30 mg of total protein, thereafter loaded in each lane of a 7.5% polyacrylamide
gel. Electrophoresis was performed at 10–15 mA and subsequently proteins
were electrotransferred on a nitrocellulose membrane (Amersham Bioscience,
Buckinghamshire, UK), 1 h at 100 mA, with a Scie-Plas semidry blotter (Scie-
Plas, Warwickshire, UK). The non-specific binding to the membrane was
blocked using 5% BSA in PBS-T buffer (PBS with 0.1% Tween-20) for 1 h at
room temperature, with constant shaking. Thereafter, the membrane was
incubated with the primary antibody, rabbit polyclonal anti-EGFR (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) at a dilution of 1:250 in PBS-T
buffer, followed by incubation with the secondary antibody, goat anti-rabbit
antibody labelled with Cy5 dye (Amersham Pharmacia Biotech, Little Chalfont,
UK) at a dilution of 1:1250 in PBS-T buffer. For fluorescence visualization, a
Typhoon 9400 scanner (Amersham Biosciences, Buckinghamshire, UK) was
used. The intensity of the bands was quantified by the ImageQuant 5.0 software
(Molecular Dynamics, Sunnyvale, CA, USA).
3. Results and discussion
In principle, PCI is able to trigger endosomal escape of intact
molecules, captured in endocytic vesicles, by disrupting the
membrane of these vesicles through photochemical treatment.
This technology is preferably performed with amphiphilic PS
which accumulate in the membranes of the endocytic vesicles
[14]. Preliminary studies confirmed the localization of the PS
used in this study, TPPS2a (meso-tetraphenylporphine with two
sulfonate groups), in endocytic vesicles prior to illumination
(data not shown). Our preliminary observations are consistent
with those reported previously [14–16].
To be functional, the PCI technique requires the accumulation
of macromolecules inside endocytic vesicles. Confocal micro-
scopy images presented a punctuated fluorescent pattern 4 h after
incubation of A431 cells with complexes made of Lipofectamine
and Alexa633-labelled siRNA (siRNA-Alexa633/LF) (red vesi-
cles), and with Alexa488-labelled Epidermal Growth Factor
(EGF-Alexa488) (green vesicles) (Fig. 1a). This fluorescent
complex of EGF was used to visualize the cellular membrane and
endosomes, resulting from the EGF-EGFR complex formation
and trafficking. The punctuated pattern, together with several
areas where red and green vesicles co-localize (yellow vesicles),
indicates the accumulation of the complexes in endocytic vesicles.
When illumination is applied after 4-h incubation of A431 cells
with siRNA-Alexa633/LF complexes and EGF-Alexa488, a
reduction of the punctuated fluorescent pattern is observed (Fig.
1b). The observed change frompunctuated to diffuse fluorescence
pattern of Alexa633 (red) throughout the cytoplasm of the cells,
suggests the release of siRNA molecules and/or siRNA/LF
complexes from the endosomes, as a result of a photo-induced
disruption of the endocytic vesicles. This indicates that PCI is a
useful tool to facilitate the endosomal escape of siRNA.
The next step was to determine whether PCI, apart from
improving the endosomal escape of complexes made of anti-
EGFR siRNA and Lipofectamine (anti-EGFR siRNA/LF),
would enhance the silencing efficiency of siRNA. The release
of the entrapped complexes from the endocytic vesicles is
known to be mainly dependent on the intensity of thephotochemical reactions (photochemical dose) [17]. Therefore,
the amount of photosensitizing compound and the duration of
light exposure are decisive variables. Fig. 3 shows the knock-
down of EGFR expression, resulting from siRNA-mediated
silencing treatment, when combined with different photochemi-
cal doses, determined by flow cytometry analysis (Fig. 2a, b).
Increasing concentrations of the photosensitizer employed in
PCI, resulted in increased knockdown of the EGFR, up to 70%
(Fig. 3a). The same trend was detected for increasing duration of
light exposure (Fig. 3b). Indeed PCI is able to enhance gene
silencing and, in fact, these results confirm that higher
photochemical doses induce more efficient release of the
complexes from the vesicles.
Increasing photochemical doses can, however, be associated
with a higher degree of cytotoxicity. The combination of
photosensitizing compounds and light has already been
explored in photodynamic therapy (PDT) [18]. In this strategy,
a general cytotoxic effect is induced by photochemical reactions
in order to eradicate cells. On the contrary, PCI aims at inducing
Fig. 2. Flow cytometry analysis. Dot plots from flow cytometry measurements
show FITC fluorescence (FITC-labelled anti-EGFR antibody) versus PI
(labelling dead cells) (a). Two controls are shown: (i) a sample of cells
incubated with non-specific FITC-labelled antibody, and (ii) a sample of cells
previously subjected to photochemical reactions (0.4 μg/ml PS; 60 s
illumination) followed by incubation with FITC-labelled anti-EGFR antibody.
The cells from quadrant R4, which are negative for PI fluorescence and positive
for FITC fluorescence, were considered for analysis. These correspond to living
cells which are labelled with the anti-EGFR antibody. Histograms of FITC
fluorescence (b), from cells displayed in R4 quadrant only, are used for relative
quantification of the expression of EGFR. Two examples are given: (i) a sample
of cells previously subjected to the same photochemical dose as mentioned
above, and (ii) a sample of cells treated with anti-EGFR siRNA/LF complexes
(160 pmol/ml of anti-EGFR siRNA) combined with PCI (same photochemical
dose). The shift towards lower values of fluorescence intensity indicates a
decrease in EGFR expression.
Fig. 3. Knockdown of EGFR expression following PCI-facilitated siRNA-
mediated silencing. The percentage of knockdown of EGFR protein expression,
calculated based on the mean fluorescence intensity times the percentage of
positive events (see Fig. 2), is plotted as function of (a) the concentration of PS
in μg/ml (for anti-EGFR siRNA/LF complexes with a final concentration of 40
pmol/ml of anti-EGFR siRNA, and 75 s of illumination), and (b) the interval of
illumination in seconds (for anti-EGFR siRNA/LF complexes with a final
concentration of 40 pmol/ml of anti-EGFR siRNA, and 0.5 μg/ml of PS
concentration).
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vesicles, for site-specific intracellular delivery. Though, PS
usually employed for PCI tend to accumulate in endocytic
membranes [14], a certain cytotoxicity is inevitably associated
with PCI. To study the cytotoxicity induced by the photo-
chemical treatment, the proliferation capacity of A431 cells was
assessed, at increasing concentrations of PS and increasing
intervals of illumination. As expected, higher amounts of
photosensitizing compound induced a reduction in cell
proliferation and the reduction in cell proliferation was more
pronounced for longer illumination intervals (Fig. 4). No effect
was detected when light alone was applied (0.0 μg/ml of PS)
and, notably, a low dark toxicity (at 0 s illumination) was
associated to the highest PS concentrations (>0.8 μg/ml of PS).Since photochemical reactions are, in both PDT and PCI,
essential, the determination of the right balance between
cytotoxicity and delivery is critical. Obviously, in case of
tumor cell treatment, the cytotoxicity induced by PCI is less of a
concern, and could even be considered an adjuvant. However,
given that the first goal of this study was to evaluate PCI as a
tool for improving siRNA delivery into the cytosol, the
subsequent experiments were performed employing PCI under
conditions that induce a low cytotoxicity, i.e., 0.4 μg/ml PS and
60 s illumination. These conditions (photochemical dose)
resulted in a modest reduction of cell proliferation (less than
10%) compared to non-illuminated controls (Fig. 4).
Fig. 5b shows the analysis of Western blot (Fig. 5a) prepared
with cell lysates obtained from samples treated with anti-EGFR
siRNA/LF complexes, with and without combination with the
PCI technique performed under the conditions mentioned
above. Here a 70% knockdown of EGFR expression was
obtained when PCI was part of the treatment, compared to 20%
knockdown when the treatment consisted of anti-EGFR siRNA/
LF complexes alone. Fig. 5b also shows no significant effect on
the expression of EGFR protein for cells subjected to
Fig. 5. Knockdown of EGFR expression following PCI-facilitated siRNA-
mediated silencing. Western blot (a): cells were treated, as described in the
Materials and methods, with 0.4 μg/ml TPPS2a and complexes with a final
concentration of 40 pmol/ml of siRNA made of anti-EGFR siRNA or non-
specific siRNA. After a 5-h incubation with the complexes or free anti-EGFR
siRNA, cells were illuminated for 60 s. Band analysis (b): the fluorescence
intensity of the bands, from two nitrocellulose membranes, is plotted in
percentages (%) compared with non-treated cells as controls. Lanes/Bars 1 and
3— non-treated cells; lanes/bars 2 and 4— anti-EGFR siRNA/LF complexes;
lane/bar 5 — free anti-EGFR siRNA; lane/bar 6 — non-specific siRNA/LF
complexes; P — EGFR protein (250 ng, Sigma-Aldrich, Zwijndrecht, The
Netherlands); open bars— without PCI; filled bars— with PCI.
Fig. 4. Reduction of cell proliferation by photochemical treatment. The
percentage of cell proliferation, determined 24 h after illumination using BrdU
incorporation, is plotted as function of PS concentration (μg/ml) with which
cells were incubated for 18 h. Three different illumination intervals were tested:
60 (●), 75 (▪) and 90 s (♦). No significant effect was determined by
illumination alone (0.0 μg/ml PS), and only a weak dark toxicity (0 s, ○) was
associated to the highest PS concentrations.
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anti-EGFR siRNA (bar 5), and complexes made of non-specific
siRNA (bar 6). The increase in silencing efficiency, detected
with Western blot, is lower than the enhancement determined by
flow cytometry in Fig. 3a (approximately 10% EGFR knock-
down for anti-EGFR siRNA/LF complexes alone, and approxi-
mately 70% EGFR knockdown when combined with PCI),
albeit that flow cytometry analysis was performed after a higher
photochemical dose (0.5 μg/ml PS and 75 s illumination). These
results, although detected with different techniques, support the
notion that PCI has an increased effect when inducing higher
cytotoxicity. However, for delivery purposes it is important to
avoid higher cytotoxicity and to keep cytotoxicity as lower as
possible.
To determine the added value of PCI for siRNA silencing
efficiency, three different doses of anti-EGFR siRNA/LF
complexes were tested. As shown in Fig. 6b, which was
obtained from an analysis of Fig. 6a, the highest concentration
of anti-EGFR siRNA, combined with PCI, induced up to 80%
knockdown of the EGFR. An equal concentration of anti-EGFR
siRNA showed a silencing efficiency of approximately 40%
without applying PCI. Additionally, Fig. 6a confirms that the
photochemical reactions induced by PCI have no significant
effect on the expression of EGFR of non-treated cells, as well as
cells incubated with complexes made of non-specific siRNA.
Considering that dose-response curves for anti-EGFR
siRNA/LF complexes are likely sigmoidal, it can be calculated
that a 50% silencing efficiency is reached when 35 pmol/ml
(95% confidence interval 32 to 38 pmol/ml) anti-EGFR
siRNA/LF complexes is combined with PCI, whereas 341
pmol/ml (95% confidence interval 317 to 368 pmol/ml) anti-
EGFR siRNA/LF complexes are needed to reach 50%
silencing without PCI (p<0.0001 (F-test)). This corresponds
to a PCI-mediated enhancement of silencing efficiency of oneorder of magnitude. These results contrast favorably with some
of the results obtained for PCI experiments with cationic lipids
as carriers for plasmid DNA. As previously reported by Høgset
et al., the effect of PCI on transfection efficiency of lipidic-
based carriers is not as predictable as for polymer-based
carriers, where PCI usually has a positive effect (e.g.,
polylysine, polyethyleneimine) [17]. In the case of transfection
with cationic lipids, some of the studies have reported a
reduction of transfection efficiency, which seem to vary
according to the cell type and lipid composition. In contrast,
our results clearly indicate that lipid-complexed nucleic acids
are delivered to a higher degree in the cytosol when PCI is
applied. This could be explained by the fact that RNAi is
processed in the cytoplasm, which, in this case, would be a
major advantage, as compared to plasmid DNA for which
intracellular trafficking to the nucleus consists of an additional
limiting step for transfection to occur.
Taken together, the present study identifies endosomal
escape as an important limiting step for siRNA silencing
efficiency. Additionally, this study demonstrates that lipid-
based carriers of nucleic acids can benefit from PCI, provided
that the site of activity of the nucleic acid concerned is localized
in the cytoplasm. Importantly, the 10-fold enhancement of
silencing efficiency obtained by virtue of the application of PCI,
would enable the minimization of siRNA concentrations to
Fig. 6. Effect of PCI on the relationship between concentration of siRNA/LF complexes and silencing efficiency. (a) Expression of EGFR, plotted as mean fluorescence
intensity times the percentage of positive events (as described in Fig. 2), was determined for cells treated with different concentrations of anti-EGFR siRNA/LF
complexes, with or without combination with PCI (for 0.4 μg/ml of PS concentration and 60 s of illumination time). Non-treated cells and cells treated with complexes
made of non-specific siRNAwere used as controls. (b) Percentage of knockdown of EGFR protein expression is plotted as function of the final concentration of anti-
EGFR siRNA present in the wells.
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of siRNA has been related to off-target effects [19] and to the
saturation of the RNAi machinery, which has already been
referred and correlated with a reduction of the degree and the
duration of siRNA-mediated silencing [20]. Therefore, any
attempt to decrease siRNA concentrations needed for silencing
should be taken into account.
One of the major advantages of PCI as a delivery tool is its
intracellular site-specific action. The fact that the photochemi-
cal-induced delivery of the specific macromolecule is confined
only to the illuminated area is an advantage for in vivo studies.
siRNA delivery would be limited to the desired cells, thereby
further reducing non-specific effects. The major challenge,
however, for this technique, is the difficulty of light to deeply
penetrate skin. Nevertheless, this has been attenuated by the
development of lasers that can be coupled into fiber optics,
which in their turn can be inserted into endoscopes. Nowadays, it
is possible to illuminate regions in the human body, previously
inaccessible, e.g., lungs, gastrointestinal tract, bladder [21].
This report demonstrates for the first time that PCI can be
used to enhance the endosomal escape of anti-EGFR siRNA/LF
complexes. The following step will be to determine the
applicability of PCI in vivo for enhancing antitumor effects of
anti-EGFR siRNA, with limited non-specific effects.Acknowledgments
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